Reed Jobs Accelerates Biotech Turnaround with AI‑Powered Yosemite Venture

Reed Jobs on AI‑Driven Cancer Research

Reed Jobs says the mission at Yosemite is clear: harness artificial intelligence to fast‑track cures while the biotech sector wrestles with a wave of patent expirations. The firm, founded three years ago, now fields ↑ 17 staff across Boston and San Francisco, a pace Jobs admits surprised him.

“We’re not chasing headlines about my surname; we’re chasing real therapies,” he told Reuters.

Meanwhile, a cluster of blockbuster drugs face loss of exclusivity around ↓ $500M in annual revenue, opening fertile ground for AI‑powered startups. Bloomberg notes that venture capital inflows into health tech have surged 42% year‑over‑year, a trend Yosemite intends to ride. Jobs adds that AI, once a curiosity, now underpins 60% of the firm’s scouting algorithm, reshaping how investors evaluate pipeline candidates.

Words by Chloe Winters (Venture Capital & Innovation Reporter).